Shin Nippon Biomedical Laboratories, Ltd.

Tokyo Stock Exchange 2395.T

Shin Nippon Biomedical Laboratories, Ltd. Cash and Short-Term Investments for the year ending March 31, 2024: USD 70.11 M

Shin Nippon Biomedical Laboratories, Ltd. Cash and Short-Term Investments is USD 70.11 M for the year ending March 31, 2024, a -11.57% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Shin Nippon Biomedical Laboratories, Ltd. Cash and Short-Term Investments for the year ending March 31, 2023 was USD 79.28 M, a 37.93% change year over year.
Shin Nippon Biomedical Laboratories, Ltd. Cash and Short-Term Investments for the year ending March 31, 2022 was USD 57.48 M, a -12.64% change year over year.
Shin Nippon Biomedical Laboratories, Ltd. Cash and Short-Term Investments for the year ending March 31, 2021 was USD 65.80 M, a 34.78% change year over year.
Shin Nippon Biomedical Laboratories, Ltd. Cash and Short-Term Investments for the year ending March 31, 2020 was USD 48.82 M, a 5.28% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

Tokyo Stock Exchange: 2395.T

Shin Nippon Biomedical Laboratories, Ltd.

CEO	Dr. Ryoichi Nagata F.F.P.M., M.D., Ph.D.
IPO Date	March 8, 2004
Location	Japan
Headquarters	St. Luke’s Tower
Employees	1,451
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials Research & Consulting

Description

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally. It offers pre-clinical laboratory services, such as good laboratory practice inspections; general and specific toxicity studies; pathological examinations; PK/PD of biopharmaceuticals, immunotoxicity tests, and antibody production; reproductive and developmental toxicity studies; pharmacology and pharmacological efficacy studies; and imaging services. The company also engages in the establishment and validation of analytical methods, analysis of biological samples, and calculation of pharmacokinetic parameters; and provides absorption, distribution, metabolism, and excretion studies using radioisotope-labeled compounds. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of nasal delivery systems, nucleic acid adjuvants, and regenerative medicines. The company was founded in 1957 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years